PRIOR AUTHORIZATION REQUEST FORM

Medicare Part D- Forteo (Teriparatide)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. For what indication is this drug being prescribed (pick one)? Osteoporosis Other
Q2. Please provide ICD code(s) for diagnosis.
 Q3. Please select which of the following that apply to the patient. Postmenopausal woman Man with primary or hypogonadal osteoporosis Man or woman with osteoporosis associated with sustained systemic glucocorticoid therapy
Q4. Is the patient at high risk for fracture defined as having low bone density with a T-score of less than -2.5?
Q5. Is the patient at high risk for fracture defined as history of previous osteoporosis-related fracture?

PRIOR AUTHORIZATION REQUEST FORM

Medicare Part D- Forteo (Teriparatide)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Yes No		
Q6. Has the patient experienced failure of oral bisphosphonate therapy defined as new fractures while on oral bisphosphonate therapy?		
☐ Yes ☐ No		
Q7. Does the patient have a contraindication or intolerance to oral bisphosphonates. Intolerance includes, but not limited to, abdominal pain, constipation, diarrhea, dyspepsia, headache, musculoskeletal pain, esophagitis, or other esophageal lesions? [Please Explain]		
☐ Yes ☐ No		
Q8. Additional Comments		

Prescriber Signature

Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document